BPG is committed to discovery and dissemination of knowledge
Letter to the Editor
Copyright ©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 115401
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.115401
Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis
Abinash Nayak, Gunanidhi Sahoo, Sudhansu Sekhar Nishank
Abinash Nayak, Gunanidhi Sahoo, Sudhansu Sekhar Nishank, Department of Zoology, Utkal University, Bhubaneshwar 751004, Odisha, India
Author contributions: Nayak A performed literature review, collection and drafting of the manuscript; Sahoo G and Nishank SS performed revision of the manuscript. All authors approved the final version to publish.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abinash Nayak, MD, Academic Fellow, Assistant Professor, Lecturer, Researcher, Department of Zoology, Utkal University, Vani Vihar, Bhubaneshwar 751004, Odisha, India. abinashnayakzoology@gmail.com
Received: October 17, 2025
Revised: October 24, 2025
Accepted: November 27, 2025
Published online: February 15, 2026
Processing time: 110 Days and 12.6 Hours
Core Tip

Core Tip: The nomogram by Yao et al represents a comprehensive tool for prognosticating outcomes in advanced human epidermal growth factor receptor 2-negative gastric cancer patients on immunochemotherapy. By incorporating immune, clinicopathological, and inflammatory markers, it achieves high discriminative power. Recent advancements in circulatory tumor DNA, artificial intelligence-radiomics, and combination therapies like claudin 18.2-targeting complement this model, highlighting the need for prospective validation to enhance clinical utility.